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Available online 20 August 2009Rheum palmatum Linn has been widely applied in the clinical treatment of diabetes mellitus. It
has been found that emodin as the major bioactive component of R. palmatum L exhibits the
competency to activate peroxisomal proliferator-activated receptor-γ (PPARγ) in vitro. So the
aim of this study was to evaluate the anti-diabetic effects of emodin through the activation of
PPARγ on high-fat diet-fed and low dose of streptozotocin (STZ)-induced diabetic mice. The
diabetic mice were intraperitoneally injected with emodin for three weeks. No changes of food
consumption and the body weight in emodin-treated mice were monitored daily during the
entire experiment. At the end of experiment, the levels of blood glucose, triglyceride and total
cholesterol in serum were signiﬁcantly decreased after emodin treatment. However, serum
high-density lipoprotein cholesterol (HDLc) concentration was signiﬁcantly elevated. The
glucose tolerance and insulin sensitivity in emodin-treated group were signiﬁcantly improved.
Furthermore, the results of quantitative RT-PCR analysis showed that emodin signiﬁcantly
elevated the mRNA expression level of PPARγ and regulated the mRNA expressions of LPL, FAT/
CD36, resistin and FABPs (ap2) in liver and adipocyte tissues. No effects on the mRNA
expressions of PPARα and PPARα-target genes were observed. Taken together, the results
suggested that the activation of PPARγ and the modulation of metabolism-related genes were
likely involved in the anti-diabetic effects of emodin.
© 2009 Elsevier B.V. All rights reserved.Keywords:
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Diabetic mice1. Introduction
Diabetes mellitus is characterized by chronic hyperglyce-
mia, disorders of lipid and carbohydrate and lipid metabolism,
and microvascular pathology in the retina, renal glomerulus
and peripheral nerves [1]. Therefore, numerous therapies in
diabetes patients have been developed to maintain the normal








All rights reserved.applied in hyperglycemia treatment. However, the exact
mechanisms of improving hyperglycemia and hypertriglycer-
idemia by herbs are not fully clear. In recent years, it has been
reported that the effects of herbs on peroxisomal proliferator-
activated receptors (PPARs) are associated with the regulation
of glucose and lipid metabolism. For example, berberine
inhibits 3T3-L1 adipocyte differentiation through the PPARγ
pathways [3]. Extracts from Astragalus membranaceus and
Pueraria thomsonii signiﬁcantly activate PPARα and PPARγ
[4]. Several isoprenols fromherbs have the dual actions on both
PPARα and PPARγ in vitro [5]. Theseﬁndings are signiﬁcant not
only for the elucidation of herbal anti-diabetic mechanism but
also for the development of novel PPARs agonists in diabetes
therapy.
Rheum palmatum Linn is one of traditional Chinese herbs
with multi-applications in anti-diabetes, anti-bacteria and
anti-renal disorders [6]. A class of hydroxyanthraquinones
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phanol have been identiﬁed as the major bioactive compo-
nents of R. palmatum L [6]. Yang and coworkers have reported
that emodin presents a very high binding afﬁnity to PPARγ in
vitro [7]. Therefore, the present study was performed to
investigate the anti-diabetic effects of emodin which was
involved in the activation of PPARγ on high-fat diet-fed and
low dose of STZ-induced diabetic mice. Moreover, we
evaluated the biochemical parameters in serum of diabetic
mice.2. Materials and methods
2.1. Animals and experimental procedures
Male C57/BL6J mice of 8-week-old were purchased from
Laboratory Animal Center of the Academy of Military Medical
Sciences (Beijing, China). The animals weremaintained under
standard conditions (12 h light–dark cycle, 24 °C) and had
free access to water and standard laboratory chow. All mice
were cared for in according to the standards of the Guide for
the Care and Use of Laboratory Animals.
The inducement of diabetic animals was carried out
according to a previous reported procedure [8]. In brief, the
animals were fed with high-fat diet for 4 weeks before
intraperitoneal (i.p) injection with 120 mg/kg streptozotocin
(STZ, sigma, USA). An equal volume of vehiclewas injected into
the control rats (n=8). The blood glucose levels in serumwere
determined by a glucosemeasuring kit (BiosinoBio-technology
and Sicence, China) using the glucose oxidase method. The
mice with fasting glucose level higher than 11 mmol/L were
considered as diabetic mice, and the diabetic mice with
consecutive 10-day hyperglycemia (11 mmol/L or greater)
were used for the experiment. The diabetic mice were
randomly divided into two groups: emodin-treated group
(n=15) and diabetic group (n=10). The untreated mice
(n=8) were matched in age and weight as the control group.
The mice in emodin-treated group were intraperitoneally
injected with emodin (98% pure, Nanjing Zelang Medical
Technology Co, China) (Fig. 1) at a dose of 1.5 mg/kg body
weight daily for 3 weeks. The diabetic group was intraper-
itoneally given the vehicle solvent (sterilized 0.9% NaCl). Body
weight and food consumption in each group were monitored
daily. Blood glucose levels were checked every 4 days. Blood
samples were obtained from the tail vein of themice and blood
glucose levels in serum were determined as described earlier.Fig. 1. Schematic structure of emodin.2.2. Glucose tolerance test (GTT) and insulin tolerance test (ITT)
The glucose tolerance test (GTT) and insulin tolerance test
(ITT)were carried out at the end of experiment. In the ITT,mice
were intraperitoneally administrated with 0.5 U/kg body
weight of bovine insulin (Sigma, USA) after 15 h fast. Blood
samples (10 µl) were collected from a cut in the tail vein of the
mice at 0, 15, 30, 45, 60, 90 and 120 min after insulin
administration, respectively. In the GTT, mice were intraper-
itoneally injected with 2 g/kg body weight of D-glucose after
15 h fast. Blood samples (10 µl)were taken froma cut in the tail
vein of the mice at 0, 30, 60, 90 and 120 min after glucose
administration, respectively. The GTT and ITT were carried out
on awake mice without anesthetization. The glucose levels in
serum were determined as described earlier.2.3. Blood biochemical analysis and tissue preparation
All animals were sacriﬁced after 3 weeks treatment of
emodin. Blood samples (1 ml) were obtained from the
abdominal vein with a microsyringe. Serum was separated
at 3000 rpm for 10 min. Serum triglyceride, total cholesterol,
high-density lipoprotein cholesterol (HDLc) and low-density
lipoprotein cholesterol (LDLc) levels were measured by using
corresponding commercially available kits (Beyotime Inc,
China) and an OLYMPUS AU400 chemistry analyzer. Liver,
subcutaneous adipocyte and skeletal muscle were immedi-
ately separated, collected and stored in liquid nitrogen.2.4. Quantitative analysis of gene expression
Total RNA was extracted from these frozen liver, subcu-
taneous adipocyte and skeletal muscle by TRIzol Reagent
(Invitrogen). Then 1 µg of total RNA was subjected to the
reverse transcription reaction. The cDNA was used as a
template to examine the mRNA expression levels of PPARγ,
PPARα, FAT/CD36, resistin, adiponectin, UCP2, UCP3, FABPs
(ap2) and LPL by using Syber green universal PCR master mix
(Toyobo, Japan). The PCR cycle was as follows: initial
denaturation at 95 °C for 5 min, followed by 40 cycles of
denaturation at 95 °C for 30 s, annealing at 55 °C for 30 s and
extension at 72 °C for 30 s. The amount of target genes was
analyzed using the ΔCt method following the normalization
through β-actin. The primers for target genes are shown in
Table 1.2.5. Statistical analysis
All data are presented as the mean±the standard
deviation. Non-parametric Kruskal–Wallis test was used to
analyze the data from the groups. If signiﬁcant differences
were detected, the individual groups were compared with
each other by the Mann–Whitney test by SPSS 13.0 software.
The comparison of the changes in gene expression levels was
performed using one way ANOVA followed by the least
signiﬁcant difference (LSD) for the multiple comparisons. A
probability of value of p<0.05 was considered to denote a
signiﬁcant difference between groups.
Table 1
Primers for real-time PCR analysis.









FABPs (ap2) TGAAGAGCATCATAACCCTG CACATTCCACCACCAGCT
LPL GCGCTCCATCCATCTCTTCAT GGCAGAGCCCTTTCTCAAATG
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In the present study,we sought to evaluate the anti-diabetic
effects of emodin on high-fat diet-fed and low dose of STZ-
induced diabetic mice. We found that the body weight of STZ-
treated mice was badly restricted after STZ administration and
started to be lower than that of the untreated mice (Fig. 2A).Fig. 2. Effects of emodin on body weight (A) and food consumption (B) in the
control group, the diabetic group and the emodin-treated diabetic group
(Emodin group). The results were represented as mean±S.D.From day 6 on, the body weight of emodin-treated mice was
rescued by emodin treatment although there was no statistical
signiﬁcant difference between the emodin-treated group and
the diabetic group (Fig. 2A). The food consumption and ﬂuid
intake (data not shown) in the diabetic groupwere higher than
those of the controls (Fig. 2B).
Serum glucose level in emodin-treated group was signiﬁ-
cantly lower than that in diabetic group (p<0.01). The
concentrations of serum triglyceride and cholesterol were
signiﬁcantly decreased after emodin treatment. However, the
level of serum HDLc in emodin-treated group was signiﬁcantly
increased compared to the diabetic group. No signiﬁcant
difference in LDLc was observed between the emodin-treated
group and the diabetic group (Table 2). Moreover, we
investigated the effects of emodin on the glucose homeostasis
and insulin sensitivity in diabetic mice, the GTT and ITT were
performed on day 21. As shown in Fig. 3A, the blood glucose
level in the diabetic group increased to a maximum at 60 min,
and then decreased slowly. In contrast, the fasting blood
glucose in emodin-treated group declined signiﬁcantly. To the
ITT, the serumglucose level in diabetic group slightly decreased
compared to the control group and the emodin-treated group
(Fig. 3B). Herein, these results indicated that the glucose
tolerance and insulin sensitivity in diabetic mice were
signiﬁcantly improvedbyemodin treatment. The ameliorations
of emodin on glucose homeostasis and hyper-triglyceridemia
in diabetic mice were agreement with the anti-diabetic and
lipid-modulating effects of emodin in dyslipidaemic–diabetic
rats induced by high-fat, low dose of STZ [9,10].
The RNA expression proﬁles of liver, subcutaneous
adipocyte and skeletal muscle in mice were assayed to
investigate themolecular mechanism of anti-diabetic effect of
emodin (Table 3). Our results showed that emodin signiﬁ-
cantly increased the mRNA expressions of PPARγ in the liver
of diabetic mice. In addition, we found that emodin treatment
signiﬁcantly elevated the expression of LPL, and signiﬁcantly
decreased the expression of FAT/CD36 in liver compared to
the diabetic group. It has shown that the mass of preheparin
LPL is positively related to the insulin sensitivity [11]. The
level of fatty acid in the liver is reduced by the reversed
expression of FAT/CD36 through controlling the inﬂux.
Therefore, the adjustment in the mRNA expressions of LPL
and FAT/CD36 by emodin contributed to the effects in the
improvement of hyperglycemia and dyslipidemia. Adipose
cells are a major target tissue for PPARγ agonists [12,13].
Emodin could promote the glucose uptake and differentiation
Table 2
Effects of emodin on serum glucose, triglyceride, cholesterol, HDLc and LDLc in the control group, the diabetic group and the emodin-treated diabetic group (mM)
Groups N Glucose Triglyceride Cholesterol HDLc LDLc
Control 8 5.42±0.71 0.34±0.02 1.94±0.07 1.29±0.06 0.19±0.03
Diabetic group 10 18.21±1.50⁎⁎ 0.56±0.04⁎ 2.11±0.05⁎ 1.00±0.12⁎ 0.26±0.02⁎
Emodin-treated diabetic group 15 10.04±3.20⁎ ## 0.41±0.02⁎ # 2.00±0.03# 1.17±0.07# 0.25±0.02⁎
⁎p<0.05 vs control, ⁎⁎p<0.01 vs control, #p<0.05 vs diabetic group, ##p<0.01 vs diabetic group. The results were represented as mean±S.D.
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In our study, emodin also had effects on the gene expression
in the subcutaneous adipocyte tissue. Emodin elevated FABPs
(ap2) and reduced the mRNA expression of resistin. The
transcription of FABPs (ap2) is under the regulation of PPARs.
FABPs (ap2) has been commonly used to evaluate the activity
of PPARγ ligands [14]. It is suggested that FABPs (ap2) plays aFig. 3. Effects of emodin on the GTT (A) and ITT (B) in the control group, the
diabetic group and the emodin-treated diabetic group (Emodin group). In
ITT, the serum glucose level was expressed as the ratio of glucose
concentrations of each time point to the baseline which was designated as
100%. The results were represented as mean±S.D. ⁎p<0.05, ⁎⁎p<0.01 vs
the diabetic group.
Table 3





Liver PPARγ 0.45±0.04⁎⁎ 0.61±0.11⁎⁎ #
LPL 0.67±0.08⁎⁎ 0.86±0.07 #
FAT/CD36 3.65±0.46⁎⁎ 1.27±0.06 ##




Resistin 1.37±0.13⁎ 0.88±0.15 ##
Adiponectin 0.82±0.09⁎ 0.91±0.05
FABPs (ap2) 1.17±0.11⁎⁎ 1.58±0.13 ##
Skeletal muscle PPARα 0.42±0.07⁎⁎ 0.39±0.12⁎⁎
UCP2 0.73±0.19 0.64±0.08⁎⁎
UCP3 0.83±0.18 0.86±0.07
The relative quantiﬁcation of target genes was presented as fold increase
compared to the control group which was normalized through β-actin to
one-fold. ⁎p<0.05 vs control, ⁎⁎p<0.01 vs control, #p<0.05 vs diabetic.
group, ##p<0.01 vs diabetic group..critical role in dyslipidemia, insulin resistance and athero-
sclerosis in humans. Thus, the expression of FABPs (ap2)
could be crucial in assaying whether emodin activates the
PPARγ expression. Although the expression level of resistin
was controversial to obesity, insulin resistance and glucose
homeostasis in various animal models and in clinical
investigations [15–17]. Many studies implicated that PPARγ
agonists treatment could directly cause a signiﬁcant decrease
in resistin concentration [18,19]. In consistent to this, we
found that emodin administration also decreased the mRNA
expression level of resistin in subcutaneous adipocyte [18,19].
The elevation of PPARγ mRNA was not noted, but the
alterations in the expressions of FABPs (ap2) and resistin
suggested that emodin modulates PPARγ-downstream genes
of the subcutaneous adipocyte in emodin-treatedmice, which
may be partly through PPARγ pathway.
In various diseases or cell models, emodin has exhibited
some other features like inﬂuencing reactive oxygen species
generation or adjusting the activity of some protein kinases
[20,21]. So, it is hard to exclude these traits from anti-
hyperglycemic effects of emodin. It is possible that some
other mechanisms may also contribute to the anti-diabetic
properties of emodin besides PPARγ activation. Our further
research will focus on this.
In summary, our results showed that emodin ameliorated
the symptoms of diabetic animals, and this effect was likely
associated with the regulation of PPARγ pathway. These
results together with the previous observations that emodin
is a potent PPARγ agonists could render it as an attractive
therapeutic agent for managing diabetes mellitus.
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